-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

Benzinga·05/22/2026 15:05:34
Listen to the news
Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.